Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



中生北控生物科技股份有限公司 BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION

(a joint stock limited company incorporated in the People's Republic of China with limited liability) (Stock Code: 8247)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

References are made to the announcement of Biosino Bio-Technology and Science Incorporation (the "**Company**") dated 28 July 2023 (the "**Announcement**") and the circular of the Company dated 11 August 2023 (the "**Circular**"). Unless otherwise stated, capitalised terms used herein shall bear the same meanings as those defined in the Circular.

The Company would like to supplement on the impact on measures relating to shareholder protection as follows:

The Board is of the view that the proposed amendments to the Articles (including the removal of the class meeting requirement from the Articles of Association following the repeal of the Mandatory Provisions) will not compromise protection of the Shareholders and will not have material impact on measures relating to the Shareholders' protection, as Domestic Shares and H Shares are regarded as one class of ordinary shares under the PRC law, and the substantive rights attached to these two kinds of Shares (including voting rights, dividends and asset distribution upon liquidation) are the same.

After the proposed amendments to the Articles take effect, the Company will continue to comply with the GEM Listing Rules to meet the core shareholder protection standards through compliance with the PRC laws in combination with its constitutional documents pursuant to Appendix 3 of the GEM Listing Rules and will further monitor its on-going compliance with these standards and notify the Stock Exchange if it becomes unable to comply with any of these standards.

Save as disclosed above, the Board confirms that all information in the Announcement and the Circular remain unchanged. This announcement is supplemental to and should be read in conjunction with the Announcement and the Circular, and in that connection, the existing English and Chinese versions of the Announcement and the Circular in the form as they are now will continue to be valid.

For and on behalf of the Board Biosino Bio-Technology and Science Incorporation Wu Lebin Chairman and Executive Director

Beijing, the PRC, 14 August 2023

As at the date of this announcement, the Board comprises:

Chairman and executive Director Mr. Wu Lebin (吳樂斌先生)

Vice chairmen and non-executive Directors Dr. Sun Zhe(孫哲博士) and Mr. Chen Zhengyong(陳正永先生)

President and executive Director Mr. Chen Peng (陳鵬先生)

Non-executive Directors Mr. Li Zhonghua (李忠華先生) and Dr. Gao Guangxia (高光俠博士)

Independent non-executive Directors Prof. Shen Zuojun (沈佐君教授), Mr. Lu Qi (陸琪先生) and Prof. Shen Jiangang (沈劍剛教授)

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, (1) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page of the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its posting and on the website of the Company at www.zhongsheng.com.cn.